Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
Src kinase inhibitor
DRUG CLASS:
Src kinase inhibitor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
dasatinib (215)
bosutinib (46)
TPX-0022 (8)
AZD0530 (7)
BAL3833 (4)
NXP900 (3)
PP2 (2)
TPX-0046 (2)
AZD 0424 (0)
JNJ-26483327 (0)
tirbanibulin ointment (0)
XL228 (0)
KX2-391 oral (0)
dasatinib (215)
bosutinib (46)
TPX-0022 (8)
AZD0530 (7)
BAL3833 (4)
NXP900 (3)
PP2 (2)
TPX-0046 (2)
AZD 0424 (0)
JNJ-26483327 (0)
tirbanibulin ointment (0)
XL228 (0)
KX2-391 oral (0)
›
Associations
(288)
News
Trials
VERI cancer hierarchy
Reset Filters
BCR-ABL1 fusion
Chronic Myeloid Leukemia
BCR-ABL1 fusion
Chronic Myeloid Leukemia
dasatinib
Sensitive: A1 - Approval
dasatinib
Sensitive
:
A1
dasatinib
Sensitive: A1 - Approval
dasatinib
Sensitive
:
A1
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
dasatinib
Sensitive: A1 - Approval
dasatinib
Sensitive
:
A1
dasatinib
Sensitive: A1 - Approval
dasatinib
Sensitive
:
A1
BCR-ABL1 fusion
Chronic Myeloid Leukemia
BCR-ABL1 fusion
Chronic Myeloid Leukemia
bosutinib
Sensitive: A1 - Approval
bosutinib
Sensitive
:
A1
bosutinib
Sensitive: A1 - Approval
bosutinib
Sensitive
:
A1
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
dasatinib
Sensitive: A1 - Approval
dasatinib
Sensitive
:
A1
dasatinib
Sensitive: A1 - Approval
dasatinib
Sensitive
:
A1
BCR-ABL1 V299L
Acute Lymphocytic Leukemia
BCR-ABL1 V299L
Acute Lymphocytic Leukemia
dasatinib
Resistant: A2 - Guideline
dasatinib
Resistant
:
A2
dasatinib
Resistant: A2 - Guideline
dasatinib
Resistant
:
A2
BCR-ABL1 F317I
Acute Lymphocytic Leukemia
BCR-ABL1 F317I
Acute Lymphocytic Leukemia
dasatinib
Resistant: A2 - Guideline
dasatinib
Resistant
:
A2
dasatinib
Resistant: A2 - Guideline
dasatinib
Resistant
:
A2
BCR-ABL1 T315I
Acute Lymphocytic Leukemia
BCR-ABL1 T315I
Acute Lymphocytic Leukemia
dasatinib
Resistant: A2 - Guideline
dasatinib
Resistant
:
A2
dasatinib
Resistant: A2 - Guideline
dasatinib
Resistant
:
A2
BCR-ABL1 V299L
Chronic Myeloid Leukemia
BCR-ABL1 V299L
Chronic Myeloid Leukemia
bosutinib
Resistant: A2 - Guideline
bosutinib
Resistant
:
A2
bosutinib
Resistant: A2 - Guideline
bosutinib
Resistant
:
A2
BCR-ABL1 T315I
Acute Lymphocytic Leukemia
BCR-ABL1 T315I
Acute Lymphocytic Leukemia
bosutinib
Resistant: A2 - Guideline
bosutinib
Resistant
:
A2
bosutinib
Resistant: A2 - Guideline
bosutinib
Resistant
:
A2
BCR-ABL1 T315I
Chronic Myeloid Leukemia
BCR-ABL1 T315I
Chronic Myeloid Leukemia
dasatinib
Resistant: A2 - Guideline
dasatinib
Resistant
:
A2
dasatinib
Resistant: A2 - Guideline
dasatinib
Resistant
:
A2
BCR-ABL1 T315I
Chronic Myeloid Leukemia
BCR-ABL1 T315I
Chronic Myeloid Leukemia
bosutinib
Resistant: A2 - Guideline
bosutinib
Resistant
:
A2
bosutinib
Resistant: A2 - Guideline
bosutinib
Resistant
:
A2
No biomarker
Chronic Myeloid Leukemia
No biomarker
Chronic Myeloid Leukemia
bosutinib
Sensitive: A2 - Guideline
bosutinib
Sensitive
:
A2
bosutinib
Sensitive: A2 - Guideline
bosutinib
Sensitive
:
A2
No biomarker
Chronic Myeloid Leukemia
No biomarker
Chronic Myeloid Leukemia
dasatinib
Sensitive: A2 - Guideline
dasatinib
Sensitive
:
A2
dasatinib
Sensitive: A2 - Guideline
dasatinib
Sensitive
:
A2
ABL2 fusion
Childhood B Acute Lymphoblastic Leukemia
ABL2 fusion
Childhood B Acute Lymphoblastic Leukemia
dasatinib
Sensitive: A2 - Guideline
dasatinib
Sensitive
:
A2
dasatinib
Sensitive: A2 - Guideline
dasatinib
Sensitive
:
A2
No biomarker
Chordoma
No biomarker
Chordoma
dasatinib
Sensitive: A2 - Guideline
dasatinib
Sensitive
:
A2
dasatinib
Sensitive: A2 - Guideline
dasatinib
Sensitive
:
A2
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
bosutinib
Sensitive: A2 - Guideline
bosutinib
Sensitive
:
A2
bosutinib
Sensitive: A2 - Guideline
bosutinib
Sensitive
:
A2
BCR-ABL1 F317L
Chronic Myeloid Leukemia
BCR-ABL1 F317L
Chronic Myeloid Leukemia
dasatinib
Resistant: A2 - Guideline
dasatinib
Resistant
:
A2
dasatinib
Resistant: A2 - Guideline
dasatinib
Resistant
:
A2
PDGFRA D842V
Gastrointestinal Stromal Tumor
PDGFRA D842V
Gastrointestinal Stromal Tumor
dasatinib
Sensitive: A2 - Guideline
dasatinib
Sensitive
:
A2
dasatinib
Sensitive: A2 - Guideline
dasatinib
Sensitive
:
A2
ABL1 fusion
Childhood B Acute Lymphoblastic Leukemia
ABL1 fusion
Childhood B Acute Lymphoblastic Leukemia
dasatinib
Sensitive: A2 - Guideline
dasatinib
Sensitive
:
A2
dasatinib
Sensitive: A2 - Guideline
dasatinib
Sensitive
:
A2
BCR-ABL1 V299L
Chronic Myeloid Leukemia
BCR-ABL1 V299L
Chronic Myeloid Leukemia
dasatinib
Resistant: A2 - Guideline
dasatinib
Resistant
:
A2
dasatinib
Resistant: A2 - Guideline
dasatinib
Resistant
:
A2
BCR-ABL1 T315A
Chronic Myeloid Leukemia
BCR-ABL1 T315A
Chronic Myeloid Leukemia
dasatinib
Resistant: A2 - Guideline
dasatinib
Resistant
:
A2
dasatinib
Resistant: A2 - Guideline
dasatinib
Resistant
:
A2
BCR-ABL1 F317I
Chronic Myeloid Leukemia
BCR-ABL1 F317I
Chronic Myeloid Leukemia
dasatinib
Resistant: A2 - Guideline
dasatinib
Resistant
:
A2
dasatinib
Resistant: A2 - Guideline
dasatinib
Resistant
:
A2
BCR-ABL1 F317V
Chronic Myeloid Leukemia
BCR-ABL1 F317V
Chronic Myeloid Leukemia
dasatinib
Resistant: A2 - Guideline
dasatinib
Resistant
:
A2
dasatinib
Resistant: A2 - Guideline
dasatinib
Resistant
:
A2
BCR-ABL1 F317C
Chronic Myeloid Leukemia
BCR-ABL1 F317C
Chronic Myeloid Leukemia
dasatinib
Resistant: A2 - Guideline
dasatinib
Resistant
:
A2
dasatinib
Resistant: A2 - Guideline
dasatinib
Resistant
:
A2
BCR-ABL1 G250E
Chronic Myeloid Leukemia
BCR-ABL1 G250E
Chronic Myeloid Leukemia
bosutinib
Resistant: A2 - Guideline
bosutinib
Resistant
:
A2
bosutinib
Resistant: A2 - Guideline
bosutinib
Resistant
:
A2
BCR-ABL1 F317L
Chronic Myeloid Leukemia
BCR-ABL1 F317L
Chronic Myeloid Leukemia
bosutinib
Resistant: A2 - Guideline
bosutinib
Resistant
:
A2
bosutinib
Resistant: A2 - Guideline
bosutinib
Resistant
:
A2
BCR-ABL1 F317L
Acute Lymphocytic Leukemia
BCR-ABL1 F317L
Acute Lymphocytic Leukemia
dasatinib
Resistant: A2 - Guideline
dasatinib
Resistant
:
A2
dasatinib
Resistant: A2 - Guideline
dasatinib
Resistant
:
A2
BCR-ABL1 V299L
Acute Lymphocytic Leukemia
BCR-ABL1 V299L
Acute Lymphocytic Leukemia
bosutinib
Resistant: A2 - Guideline
bosutinib
Resistant
:
A2
bosutinib
Resistant: A2 - Guideline
bosutinib
Resistant
:
A2
BCR-ABL1 F317C
Acute Lymphocytic Leukemia
BCR-ABL1 F317C
Acute Lymphocytic Leukemia
dasatinib
Resistant: A2 - Guideline
dasatinib
Resistant
:
A2
dasatinib
Resistant: A2 - Guideline
dasatinib
Resistant
:
A2
BCR-ABL1 F317V
Acute Lymphocytic Leukemia
BCR-ABL1 F317V
Acute Lymphocytic Leukemia
dasatinib
Resistant: A2 - Guideline
dasatinib
Resistant
:
A2
dasatinib
Resistant: A2 - Guideline
dasatinib
Resistant
:
A2
BCR-ABL1 T315A
Acute Lymphocytic Leukemia
BCR-ABL1 T315A
Acute Lymphocytic Leukemia
dasatinib
Resistant: A2 - Guideline
dasatinib
Resistant
:
A2
dasatinib
Resistant: A2 - Guideline
dasatinib
Resistant
:
A2
BCR-ABL1 F317L
Acute Lymphocytic Leukemia
BCR-ABL1 F317L
Acute Lymphocytic Leukemia
bosutinib
Resistant: A2 - Guideline
bosutinib
Resistant
:
A2
bosutinib
Resistant: A2 - Guideline
bosutinib
Resistant
:
A2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login